Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.75 |
| ▸ | TP53 | P04637 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 8/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.72 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | USP7 | Q93009 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221128 | 0.90 | SMN1; SMN2 (0.89) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2219373 | 0.89 | KMT2A (0.86) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2218247 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2219477 | 0.86 | KMT2A (0.96) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL31069695 | 0.85 | MEN1 (0.96) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2218102 | 0.85 | MEN1 (0.96) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL31069697 | 0.85 | MEN1 (0.96) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2226684 | 0.84 | MAPT (0.64) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL2222250 | 0.83 | USP7 (1.00) | SMN1; SMN2TP53HTTNPC1RAB9A | |
| SCHEMBL20864349 | 0.82 | MAPT (0.73) | SMN1; SMN2TP53HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177105-A1 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | US | claimed |
| EP-2357176-A1 | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 | Hybrigenics S.A. (FR) | 2011-08-17 | — | — | EP | disclosed |
| US-20110177105-A1 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications | HYBRIGENICS SA (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177105-A1 | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications | USP7, SENP7, PSMA7 | SMN1; SMN2 2877/4885TP53 330/4885HTT 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.